May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
The Gly252arg Myocilin Mutation Confers Glaucoma of Intermediate Severity
S.L. Bennett; A.W. Hewitt; J.E. Richards; A.P. Booth; C. Inglehearn; R. Anwar; L.S. Kearns; E.M. Stone; J.E. Craig; D.A. Mackey
Author Affiliations & Notes
  • S.L. Bennett
    Clinical Genetics Unit, Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia
  • A.W. Hewitt
    Clinical Genetics Unit, Eye Research Australia, University of Melbourne, Royal Victorian Eye & Ear Hospital, East Melbourne, Australia
    Department of Ophthalmology, Flinders University, Adelaide, Australia
  • J.E. Richards
    Department of Ophthalmology, University of Michigan, Ann Arbor, MI
  • A.P. Booth
    Molecular Medicine Unit, Clinical Sciences Building, St James's University Hospital, Leeds, United Kingdom
  • C. Inglehearn
    Molecular Medicine Unit, Clinical Sciences Building, St James's University Hospital, Leeds, United Kingdom
  • R. Anwar
    Molecular Medicine Unit, Clinical Sciences Building, St James's University Hospital, Leeds, United Kingdom
  • L.S. Kearns
    Clinical Genetics Unit, Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia
  • E.M. Stone
    Center for Macular Degeneration, Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinics, Iowa City, IA
  • J.E. Craig
    Department of Ophthalmology, Flinders University, Adelaide, Australia
  • D.A. Mackey
    Clinical Genetics Unit, Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia
    Department of Ophthalmology, University of Tasmania, Royal Hobart Hospital, Hobart, Australia
  • Footnotes
    Commercial Relationships  S.L. Bennett, None; A.W. Hewitt, None; J.E. Richards, None; A.P. Booth, None; C. Inglehearn, None; R. Anwar, None; L.S. Kearns, None; E.M. Stone, None; J.E. Craig, None; D.A. Mackey, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 187. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      The Gly252arg Myocilin Mutation Confers Glaucoma of Intermediate Severity
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      S.L. Bennett, A.W. Hewitt, J.E. Richards, A.P. Booth, C. Inglehearn, R. Anwar, L.S. Kearns, E.M. Stone, J.E. Craig, D.A. Mackey; The Gly252arg Myocilin Mutation Confers Glaucoma of Intermediate Severity . Invest. Ophthalmol. Vis. Sci. 2006;47(13):187.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : The purpose of this study is to examine the phenotype of an Australian pedigree with the Gly252Ala myocilin mutation and compare it to previously published descriptions of pedigrees carrying the same mutation.

Methods: : All recruited subjects underwent a comprehensive clinical examination, including: optic disc assessment; pachymetry; applanation tonometry; and visual field measurement. All data presented are the mean ± standard deviation. Mutation analysis was performed through direct sequencing. Haplotype analysis was performed using microsatellite markers around the myocilin gene.

Results: : Eight glaucoma affected people were identified from the same Australian pedigree. Their mean age at diagnosis was 41.5 ± 8.2 years (range 32 to 57). The mean age at review was 61.4 ± 13.9 years. The highest recorded intraocular pressure (IOP) ranged from 26 to 42mmHg (mean: 31.8 ± 6.4). The median central corneal thickness was 521µm (range 492–560µm). Cup to disc ratios in the worst eye ranged from 0.6 to 0.9. Five of these individuals have undergone filtration surgery. The mean age at glaucoma diagnosis in the published literature for Scottish and American patients with the Gly252Ala myocilin mutation is approximately 30.1 ± 6.9 years, whilst the mean highest recorded IOP is 42.6 ± 14.2mmHg. A common founding haplotype between MY5 and D1S218 was found across our pedigrees and affected individuals living in Scotland and the United States of America.

Conclusions: : Although a common founder for this mutation across the world was found, the phenotype from this Australian Gly252Arg myocilin mutation carrying pedigree is less severe than described in the literature. Our results indicate that the Gly252Arg mutation may be less severe than the Thr377Met mutation though more severe than the Gln368Stop mutation.

Keywords: genetics • mutations 
© 2006, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2015 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept